Revenue at Rs 2,223 Cr for Q3FY22, up 18%; EBITDA at Rs. 537 Cr, up 28%. Generics - three new approvals, partnership with Tabuk Pharmaceuticals for expansion into the Middle East and North Africa. Biosimilars - interchangeable bGlargine launched in US and received...